The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications
Its allowed us to move from animal studies to clinical trials within less than a year of the publication of the animal study, which, as far as I know, is unprecedented and extremely exciting
T., Reynolds, J
Neurological Health BPC-157 is also evidenced to have neuroprotective effects, reducing nerve damage due to strokes and injuries while regulating neurotransmitters to attenuate symptoms of Parkinsons disease, schizophrenia, and depression [2, 33, 36]

At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity